Prevacid (Lansoprazole): Indications, Dosing, and Precautions
Prevacid (lansoprazole) is FDA-approved for treating frequent heartburn in adults ≥18 years at 15 mg once daily for 14 days, with the option to repeat courses every 4 months. 1
FDA-Approved Adult Indications & Dosing
For over-the-counter use:
- Frequent heartburn (≥2 days/week): 15 mg once daily for 14 days, taken before eating in the morning
- May take 1-4 days for full effect
- Can repeat 14-day courses every 4 months if needed
- Do not exceed 14 days per course or use more frequently than every 4 months without physician direction 1
For prescription use (based on clinical evidence):
- Erosive esophagitis: 30 mg once daily for 8 weeks 2, 3
- Duodenal/gastric ulcers: 30 mg once daily 2, 3
- GERD maintenance: 15-30 mg once daily 4
- H. pylori eradication: 30 mg twice daily combined with antibiotics for 10-14 days 5
- NSAID ulcer prevention: 15 mg daily 6
Pediatric Dosing (Ages 1-17 Years)
Lansoprazole is FDA-approved for children ages 1-17 years with GERD and erosive esophagitis at weight-based dosing of 0.7-3.0 mg/kg/day. 7
Specific pediatric dosing:
- Weight ≤30 kg: 15 mg once daily
- Weight >30 kg: 30 mg once daily
- Dosing range studied: 0.7-3.0 mg/kg/day, with doses up to 1.3 mg/kg/day shown safe 7, 8
Formulation options for children:
- Sprinkle capsule contents onto soft foods or select juices
- Administer through nasogastric tube (≥8 French) in juice
- Strawberry-flavored orally disintegrating tablets 7
Critical Pediatric Considerations
PPIs should NOT be used routinely in infants with uncomplicated reflux. Placebo-controlled trials demonstrate no superiority over placebo for reducing irritability in infants, and acid suppression increases risks of respiratory infections, gastroenteritis, candidemia, and necrotizing enterocolitis in preterm infants. 7
Reserve PPI therapy in children for:
- Documented erosive esophagitis
- Esophagitis refractory to H2-receptor antagonists
- Severe GERD symptoms with objective evidence 7
Administration Guidelines
Optimal timing: 30-60 minutes before meals for prescription-strength dosing (though OTC formulation specifies "before eating in the morning") 9, 1
Swallow capsules whole - do not crush or chew 1
For extemporaneous suspension (pediatric):
- 3 mg/mL in 8.4% sodium bicarbonate
- Refrigerated: stable up to 7 days only
- Room temperature: stable only 48 hours
- Do not use previously reported 14-day expiration 10
Key Precautions & Safety Concerns
Long-term Use Warnings
Chronic PPI use carries significant risks:
- Community-acquired pneumonia
- Gastroenteritis and Clostridioides difficile infection
- Enterochromaffin cell hyperplasia (up to 50% of children on PPIs >2.5 years)
- Potential increased fracture risk with prolonged use 7
Drug Interactions
Lansoprazole is metabolized via CYP2C19 and CYP3A4 pathways, though it shows less pharmacokinetic variability than some other PPIs. Consider potential interactions with drugs metabolized by these pathways. 2, 11
When NOT to Use
Do not use lansoprazole as first-line therapy for:
- Uncomplicated infant reflux (use conservative management) 7
- Non-erosive GERD without trial of lifestyle modifications
- Dyspepsia without alarm symptoms (try empiric therapy first) 9
Alarm symptoms requiring endoscopy before PPI therapy:
- Dysphagia
- Bleeding or anemia
- Unintentional weight loss
- Recurrent vomiting 9
Comparative Efficacy
Lansoprazole demonstrates superior efficacy to H2-receptor antagonists for healing erosive esophagitis and symptom relief, with healing rates >90% in most studies. 7, 2, 4
Lansoprazole vs. other PPIs: Comparable efficacy to omeprazole 20 mg, pantoprazole 40 mg, and other standard-dose PPIs for most indications, with minimal clinically significant differences. 9, 4, 11
For H. pylori eradication: Lansoprazole-based triple therapy achieves 71-94% eradication rates, though newer potassium-competitive acid blockers may offer superior results (92% vs 80% with PPIs). 12, 5, 4
Adverse Effects
Common (≤5-14% in short-term use):
Pediatric-specific: Constipation and headache were most common treatment-related events in children, occurring in <20% of patients. Safety profile acceptable with mean exposure ~50 days. 8
Serious but rare: Elevated serum gastrin levels occur (mean increase from 58 to 122 pg/mL) but median values remain within normal range. Clinical significance of chronic hypergastrinemia requires monitoring in long-term use. 8
Clinical Pearls
- Twice-daily dosing (7.5 mg BID) produces faster symptom response than once-daily dosing (15 mg QD) in infants, though overall efficacy at 2 weeks is equivalent 13
- Nighttime heartburn: Both 15 mg and 30 mg doses significantly reduce nighttime heartburn (61% vs 48% placebo), with benefit evident on day 1 14
- NSAID ulcer prevention: 15 mg daily reduces ulcer recurrence risk by 75% compared to gefarnate (hazard ratio 0.25) 6
- Tachyphylaxis does not occur with PPIs (unlike H2-receptor antagonists, which develop tolerance within 6 weeks) 7